Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-08-01
1993-12-28
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
540456, 514183, A61K 31395, C07D49116
Patent
active
052739791
ABSTRACT:
Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated derivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
REFERENCES:
patent: 3244592 (1966-04-01), Arai
J. Antibiotics A15, pp. 231-232, by Arai (1962).
Arison Byron H.
Beattie Thomas R.
Chen Shieh-Shung T.
Dezeny Georgette
Dumont Francis
Bond Robert T.
Caruso Charles M.
Merck & Co. , Inc.
Thies J. Eric
LandOfFree
C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1542832